Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Èíôîðìàöèÿ è êîììåð÷åñêàÿ ðåêëàìà > Ëåêàðñòâåííûå ïðåïàðàòû

Ëåêàðñòâåííûå ïðåïàðàòû Ðàçìåùåíèå ðåêëàìû ïëàòíîå. Ïèøèòå.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 17.09.2009, 17:30
Shahla Shahla âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 10.04.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 1,732
Ïîáëàãîäàðèëè 460 ðàç(à) çà 445 ñîîáùåíèé
Shahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
1.Ñóëüôàýòèäîë. 2. Òàáëåòêè â ôîðìå ER, MR è XL-ýòî îäíî è òî æå?

Çäðàâñòâóéòå!
1.Ïåðåä òåì êàê ñïðîñèòü íà ôîðóìå, ïðèìåíÿåòñÿ ëè â Ðîññèè ñóëüôàýòèäîë, è ìîæíî ëè íà ðûíêå îáîéòèñü áåç íåãî, ÿ ïîèñêàëà â áàçàõ äàííûõ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ], [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ], up-to-date- 0 ðåçóëüòàòîâ.
Îáçîð pubmed ïîçâîëÿåò ñäåëàòü âûâîäû, ÷òî ïîñëå 70-õ ãîäîâ ïðåïàðàò íå ïðèìåíÿëñÿ; ðàáîòû ïîñëåäíèõ ëåò ïîñâÿùåíû òîìó, êàê óäàëÿòü ýòè ïðåïàðàòû èç êðîâè.
Ñóëüôàýòèäîë+ 0,05 ã+ áåíçîêàèí+êîíöåíòðàò îáëåïèõîâîãî ìàñëà â ôîðìå ñâå÷åé.
Áåíçîêàèí, êñòàòè, ñíèæàåò àíòèáàêòåðèàëüíóþ àêòèâíîñòü ñóëüôîíàìèäîâ.

2. Ñðàâíèâàëè 2 ïðåïàðàòà òàáëåòêè êëàðèòðîìèöèíà ER extended release è
XL, MR- ýòî îäíî è òî æå? (òîæå äîëãî èñêàëà, ÷òîáû íå áåñïîêîèòü âðà÷åé, íå íàøëà).

Ïîìîãèòå, ïîæàëóéñòà, î÷åíü ðàññ÷èòûâàþ íà âàøó ïîìîùü.
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà.
Òåðàïåâò, ïóëüìîíîëîã.
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 18.09.2009, 16:49
Àâàòàð äëÿ Dr.
Dr. Dr. âíå ôîðóìà
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 29.07.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 10,123
Ïîáëàãîäàðèëè 446 ðàç(à) çà 427 ñîîáùåíèé
Dr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íó, íàâåðíîå, áåç ñóëüôàíèëàìèäîâ ìîæíî âîîáùå îáîéòèñü. Êðîìå áèñåïòîëà ïðè ïíåâìîöèñòíîé ïíåâìîíèè. Ïðî MR íàäî ïîäóìàòü, à îñòàëüíîå âñå îäíî è òî æå, ðåòàðäíûå ôîðìû.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 18.09.2009, 18:00
Àâàòàð äëÿ Dr.
Dr. Dr. âíå ôîðóìà
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 29.07.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 10,123
Ïîáëàãîäàðèëè 446 ðàç(à) çà 427 ñîîáùåíèé
Dr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Êñòàòè, èçâåñòåí äîêòîð, ïîëó÷èâøèé ñðåäè êîëëåã êëè÷êó "Íîðñóëüôàçîë" çà áîëåçíåííîå ïðèñòðàñòèå ê íàçíà÷åíèþ ýòîãî ïðåïàðàòà
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 22.09.2009, 14:35
Àâàòàð äëÿ Tihoma
Tihoma Tihoma âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 11.08.2009
Ãîðîä: Ñ-Ïåòåðáóðã
Ñîîáùåíèé: 2,188
Ñêàçàë(à) ñïàñèáî: 13
Ïîáëàãîäàðèëè 630 ðàç(à) çà 588 ñîîáùåíèé
Tihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òîðãîâîå íàçâàíèå ñóëüôýòèäîëà - Ýòàçîë, ñòàðèííûé, åùå ñ ñîâåòñêèõ âðåìåí èçâåñòíûé ïðåïàðàò. Äî ñèõ ïîð ïðîèçâîäèòñÿ è, íàâåðíîå, êåì-òî ïîêóïàåòñÿ, õîòÿ, äåéñòâèòåëüíî, íèêàêîé íåîáõîäèìîñòè â åãî ïðèñóòñòâèè íà ðûíêå íåò,
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 22.09.2009, 19:13
Shahla Shahla âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 10.04.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 1,732
Ïîáëàãîäàðèëè 460 ðàç(à) çà 445 ñîîáùåíèé
Shahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äà, ÿ íàøëà â Ìàøêîâñêîì çà 1986 ãîä ýòàçîë. Òàêæå ÿ íå áåç óäèâëåíèÿ îáíàðóæèëà, ÷òî ñóëüôîíàìèäû íå ñïèñàíû ñî ñ÷åòîâ äàæå â ÑØÀ, è ïðèìåíÿþò äàæå â äåòñêîé ïðàêòèêå:
SULFONAMIDE ANTIBIOTICS — sulfadiazine and sulfamethoxazole which are now being used in higher than usual doses to treat toxoplasmosis in patients with AIDS.
Sulfadiazine: Drug information
Prevention of recurrent attacks of rheumatic fever (unlabeled use): 1 g/day
USE — Treatment of urinary tract infections and nocardiosis; adjunctive treatment in toxoplasmosis; uncomplicated attack of malaria
Sulfadiazine: Pediatric drug information
USE — Adjunctive treatment in toxoplasmosis; treatment of urinary tract infections and nocardiosis; rheumatic fever prophylaxis in penicillin-allergic patient; uncomplicated attack of malaria

Sulfisoxazole: Drug information
U.S. BRAND NAMES — Gantrisin®

USE — Treatment of urinary tract infections, otitis media, Chlamydia; nocardiosis
Erythromycin and sulfisoxazole


U.S. BRAND NAMES — Pediazole® [DSC]
USE — Treatment of susceptible bacterial infections of the upper and lower respiratory tract, otitis media in children caused by susceptible strains of Haemophilus influenzae, and many other infections in patients allergic to penicillin

Sulfacetamide: Patient drug information
U.S. BRAND NAMES — Bleph®-10;...
USE
Ophthalmic: Treatment and prophylaxis of conjunctivitis due to susceptible organisms; corneal ulcers; adjunctive treatment with systemic sulfonamides for therapy of trachoma
Dermatologic: Scaling dermatosis (seborrheic); bacterial infections of the skin; acne vulgaris
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà.
Òåðàïåâò, ïóëüìîíîëîã.
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 22.09.2009, 21:40
Àâàòàð äëÿ Tihoma
Tihoma Tihoma âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 11.08.2009
Ãîðîä: Ñ-Ïåòåðáóðã
Ñîîáùåíèé: 2,188
Ñêàçàë(à) ñïàñèáî: 13
Ïîáëàãîäàðèëè 630 ðàç(à) çà 588 ñîîáùåíèé
Tihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñóëüôàäèàçèí ñåðåáðà ïðèìåíÿåòñÿ âî ìíîãèõ ñòðàíàõ (è â Ðîññèè) êàê ìåñòíîå ñðåäñòâî äëÿ ëå÷åíèÿ îæîãîâ, ïðîëåæíåé, èíôèöèðîâàííûõ ðàí. Ñóëüôàöåòàìèä - îí æå ñóëüôàöèë-íàòðèé, àëüáóöèä - äî ñèõ ïîð øèðîêî ïðèìåíÿåòñÿ â îôòàëüìîëîãèè. Ïðîáëåìà â òîì, ÷òî áëàãîäàðÿ áåñêîíòðîëüíîìó è áåçðåöåïòóðíîìó ïîòðåáëåíèþ Áèñåïòîëà, Ýòàçîëà, Ôòàëàçîëà è ò.ä., íà ïîñòñîâåòñêîì ïðîñòðàíñòâå î÷åíü âåëèêà äîëÿ ðåçèñòåíòíûõ ê ñóëüôîíèëàìèäàì ìèêðîîðãàíèçìîâ - â îòëè÷èå îò îñòàëüíîãî ìèðà, ãäå ïîòðåáëåíèå ýòèõ ïðåïàðàòîâ áûëî âåñüìà îãðàíè÷åííûì. Ïîýòîìó â çàðóáåæíûõ ðóêîâîäñòâàõ îíè âñòðå÷àþòñÿ íåðåäêî, à âîò â îòå÷åñòâåííîé ïðàêòèêå ñåáÿ óæå ïî÷òè èçæèëè. Ïîäðîáíåå, íàïðèìåð: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 08:09.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.